Life Sciences Tools and Services
Company Overview of Wolfe Laboratories, Inc.
Wolfe Laboratories, Inc. provides contract research and development services to the pharmaceutical and biotechnology industries. The company specializes in pre-clinical formulation development for small molecules, proteins, and peptides as solutions and dispersed systems. It offers various pre-clinical services, including pre-formulation and formulation development, analytical method development and characterization, PK and in vitro ADME bioanalytical development, dose formulation stability and uniformity assessment, and lyophilization services. The company was founded in 1999 and is based in Watertown, Massachusetts.
134 Coolidge Avenue
Watertown, MA 02472
Founded in 1999
Key Executives for Wolfe Laboratories, Inc.
Founder, Chief Executive Officer and President
Senior Vice President and General Counsel
Vice President of Pharmaceutical Development
Compensation as of Fiscal Year 2016.
Wolfe Laboratories, Inc. Key Developments
Wolfe Laboratories, Inc. Announces the Appointment of Frank Tagliaferri as Vice President, Pharmaceutical Development, Effective Immediately
Jun 14 16
Wolfe Laboratories, Inc. announced that Frank Tagliaferri, Ph.D., has been appointed Vice President, Pharmaceutical Development, effective immediately. Dr. Tagliaferri will lead technical operations for Wolfe’s rapidly growing client base, bringing a wealth of experience in analytical
methodologies, formulation and process development, scale-up, and regulatory functions across highly diverse therapeutic modalities, including small molecules, peptides, proteins, and nucleic acid therapeutics. Dr. Tagliaferri will serve as a member of Wolfe’s executive leadership team and will report to Janet Wolfe, the company's President and Chief Executive Officer. Most recently, Dr. Tagliaferri co-founded and served as Vice President of R&D at 4P Therapeutics with a focus on the design, characterization, and commercial development of novel delivery systems and drug/device combination products for biologics and other complex molecules.
Paul Oakley Joins Wolfe Laboratories, Inc. as Senior Vice President and General Counsel
May 17 16
Wolfe Laboratories, Inc. announced the expansion of its senior management team through the addition of Paul Oakley, who has joined as Senior Vice President and General Counsel. In this role, Mr. Oakley will be responsible for the company’s corporate and financial strategies and general operations. Mr. Oakley will be reporting to Janet Wolfe, President and CEO of Wolfe Laboratories. Mr. Oakley brings more than 20 years of experience as an executive and entrepreneur, building and managing high-growth, mission-oriented teams and organizations, as well as an external general counsel for a vast portfolio of emerging growth companies. Prior to joining Wolfe, Mr. Oakley served as Chief Administrative Officer for Truelight, LLC. He was also responsible for delivering analytics and business intelligence solutions to the $78 billion-and-growing competitive retail electricity supply sector and to the multi-billion-dollar clean energy development community through its subsidiary, TrueLight Energy, LLC.
Wolfe Laboratories, Inc. Expands its Integrated Pharmaceutical Development Operations
Feb 16 16
Wolfe Laboratories, Inc. announced its expansion of the company's analytical, formulation and process development capabilities. The company has relocated to its 17,595 square feet of laboratory and office space at 19 Presidential Way in Woburn, Massachusetts. The expansion builds upon company’ existing pharmaceutical development capabilities, and will support continued innovation in the development of small molecules, biologics, antibody drug conjugates and nucleic acid therapeutics. The company’s clients depend upon its expeditious scientific acumen of their development programs, which support IND enabling, clinical advancement and commercialization of innovative drug products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|